Stocks / NASDAQ / Foamix Pharmaceuticals Ltd.

Foamix Pharmaceuticals Ltd.

Industry:   Consumer Durables - Specialty Chemicals Stock Symbol:   FOMX - NASDAQ Animal Usage:   Animal Testing

Our Opinion

Foamix Pharmaceuticals Ltd. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.

Supporting Evidence:

The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.

“We currently intend to use the net proceeds we receive from this offering as approximately $20–$25 million to conduct Phase III clinical trials and other pre-launch studies, including any animal and human toxicology studies, for FMX101 for the treatment of moderate-to-severe acne.” Read the full article.

Company Description

Foamix Pharmaceuticals Ltd. engages in the development and commercialization of proprietary minocycline foam for the treatment of acne, impetigo, and other skin conditions. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. [Source: MarketWatch]

Company Website: http://www.foamix.co.il

Contact:   http://www.foamix.co.il/contact.asp; IR: david.domzalski@foamixpharma.com;